Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aquestive Therapeutics In...

    NASDAQ: AQST · Real-Time Price · USD
    3.54
    0.12 (3.51%)
    At close: Jun 16, 2025, 3:59 PM
    3.44
    -2.64%
    After-hours: Jun 16, 2025, 07:26 PM EDT

    Aquestive Therapeutics Statistics

    Share Statistics

    Aquestive Therapeutics has 99.33M shares outstanding. The number of shares has increased by 8.6% in one year.

    Shares Outstanding

    n/a
    		 99.33M

    Shares Change (YoY)

    n/a
    		 8.6%

    Shares Change (QoQ)

    n/a
    		 8.44%

    Owned by Institutions (%)

    n/a
    		 47.63%

    Shares Floating

    n/a
    		 91.68M

    Failed to Deliver (FTD) Shares

    n/a
    		 16,752

    FTD / Avg. Volume

    n/a
    		 1.11%

    Short Selling Information

    The latest short interest is 11.14M, so 11.21% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 11.14M

    Short % of Shares Out

    n/a
    		 11.21%

    Short % of Float

    n/a
    		 13.3%

    Short Ratio (days to cover)

    n/a
    		 8.7

    Valuation Ratios

    The PE ratio is -7 and the forward PE ratio is -5.79. Aquestive Therapeutics's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 -7

    Forward PE

    n/a
    		 -5.79

    PS Ratio

    n/a
    		 5.36

    Forward PS

    n/a
    		 1.5

    PB Ratio

    n/a
    		 -5.13

    P/FCF Ratio

    n/a
    		 -8.6

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Aquestive Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.68, with a Debt / Equity ratio of -0.63.

    Current Ratio

    n/a
    		 4.68

    Quick Ratio

    n/a
    		 4.36

    Debt / Equity

    n/a
    		 -0.63

    Debt / EBITDA

    n/a
    		 -1.43

    Debt / FCF

    n/a
    		 -1.06

    Interest Coverage

    n/a
    		 -1.83

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $405,359.15

    Profits Per Employee

    n/a
    		 $-310,823.94

    Employee Count

    n/a
    		 142

    Asset Turnover

    n/a
    		 0.57

    Inventory Turnover

    n/a
    		 2.96

    Taxes

    Income Tax

    n/a
    		 -14K

    Effective Tax Rate

    n/a
    		 0.03%

    Stock Price Statistics

    The stock price has increased by 29.67% in the last 52 weeks. The beta is 1.93, so Aquestive Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.93

    52-Week Price Change

    n/a
    		 29.67%

    50-Day Moving Average

    n/a
    		 2.79

    200-Day Moving Average

    n/a
    		 3.67

    Relative Strength Index (RSI)

    n/a
    		 66.46

    Average Volume (20 Days)

    n/a
    		 1,507,301

    Income Statement

    In the last 12 months, Aquestive Therapeutics had revenue of 57.56M and earned -44.14M in profits. Earnings per share was -0.51.

    Revenue

    n/a
    		 57.56M

    Gross Profit

    n/a
    		 39.69M

    Operating Income

    n/a
    		 -30.77M

    Net Income

    n/a
    		 -44.14M

    EBITDA

    n/a
    		 -26.62M

    EBIT

    n/a
    		 -27.33M

    Earnings Per Share (EPS)

    n/a
    		 -0.51
    Full Income Statement

    Balance Sheet

    The company has 71.55M in cash and 38M in debt, giving a net cash position of 33.54M.

    Cash & Cash Equivalents

    n/a
    		 71.55M

    Total Debt

    n/a
    		 38M

    Net Cash

    n/a
    		 33.54M

    Retained Earnings

    n/a
    		 -363.21M

    Total Assets

    n/a
    		 102.23M

    Working Capital

    n/a
    		 70.87M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -35.76M and capital expenditures -159K, giving a free cash flow of -35.92M.

    Operating Cash Flow

    n/a
    		 -35.76M

    Capital Expenditures

    n/a
    		 -159K

    Free Cash Flow

    n/a
    		 -35.92M

    FCF Per Share

    n/a
    		 -0.41
    Full Cash Flow Statement

    Margins

    Gross margin is 68.95%, with operating and profit margins of -53.46% and -76.68%.

    Gross Margin

    n/a
    		 68.95%

    Operating Margin

    n/a
    		 -53.46%

    Pretax Margin

    n/a
    		 -76.7%

    Profit Margin

    n/a
    		 -76.68%

    EBITDA Margin

    n/a
    		 -46.24%

    EBIT Margin

    n/a
    		 -53.46%

    FCF Margin

    n/a
    		 -62.4%

    Dividends & Yields

    AQST does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AQST is $9.5, which is 168.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $9.5

    Price Target Difference

    n/a
    		 168.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.18

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist